P103 ROLE OF INFLIXIMAB IN THE MANAGEMENT OF IMMUNE-CHECKPOINT INHIBITORS-MEDIATED COLITIS (ICI-C)

Immune-checkpoint inhibitors (ICI) had made good success in in many cancer types for the past 5-10 years, meanwhile, ICI also lead to serious complications e.g. colitis. The management strategy involves high dose steroid with known significant side effects, and biologic, e.g. infliximab based on small scale studies. We conducted this retrospective study to evaluate the role of infliximab in the treatment of ICI-C.